Aging Cells Fight Cancer But May Help It Spread

Scientists have uncovered a striking paradox in how aging affects cancer: while senescent cells can slow tumor growth, they may simultaneously create conditions that help cancer spread to other organs.

Research published in Aging reveals that different types of aging cells have dramatically different effects on cancer progression, with some acting as tumor suppressors and others inadvertently promoting metastasis.

The findings challenge conventional wisdom about the relationship between aging and cancer, suggesting that therapeutic strategies targeting senescent cells need to be far more precise than previously thought. The study could reshape how doctors approach cancer treatment in older patients, who make up the vast majority of cancer cases.

The Double-Edged Sword of Cellular Aging

Using genetically modified mice, researchers at the University of Texas Health Sciences Center systematically shut down telomerase—the enzyme that maintains chromosome ends—in three specific cell types: immune cells, connective tissue cells, and blood vessel cells. This forced these cells into senescence, a state where they stop dividing and begin secreting inflammatory signals.

When the team implanted breast, prostate, and pancreatic cancer cells into these mice, they discovered that aging in immune and connective tissue cells consistently slowed tumor growth. However, this apparent benefit came with a troubling cost: the tumors showed increased tissue damage and signs of becoming more aggressive.

The most dramatic effects occurred when blood vessel cells were forced into senescence. These tumors not only shrank but became starved of oxygen due to poor blood supply. Yet this oxygen deprivation created an unexpected danger—pancreatic cancer cells became significantly more likely to spread to the liver.

When Oxygen Starvation Backfires

The research revealed why targeting blood vessel aging might be particularly risky. When endothelial cells that line blood vessels become senescent, they form abnormal, leaky vessels that can’t properly nourish tumors. While this initially seems beneficial, the resulting low-oxygen environment triggers a survival response in cancer cells.

Key findings from the blood vessel studies include:

• Vascular breakdown: Blood vessels became smaller, less functional, and leaked extensively
• Oxygen crisis: Tumors showed massive activation of hypoxia-inducible factor, a protein that helps cells survive low-oxygen conditions
• Metabolic shift: Cancer cells dramatically increased glucose consumption to survive without adequate oxygen
• Metastatic advantage: Only mice with aged blood vessel cells developed liver metastases

This pattern mirrors what happens in aggressive human cancers, where poor blood supply often correlates with increased likelihood of metastasis.

The Inflammatory Connection

When immune cells were forced into senescence, tumors grew more slowly but developed increased fibrous tissue and inflammation. The study suggests this occurs because aging immune cells shift toward producing inflammatory signals that can paradoxically both fight cancer and promote tissue remodeling that may help tumors adapt.

Similarly, aging connective tissue cells created environments with extensive scar-like tissue formation around tumors. While this appeared to constrain tumor growth initially, it also led to loss of normal cellular organization—a hallmark of cancer progression.

Remarkably, the researchers found increased expression of a gene called Plod2 in the aged blood vessel cells through RNA sequencing analysis. This gene is known to promote epithelial-to-mesenchymal transition, a process that helps cancer cells become more mobile and invasive—explaining the increased metastasis observed in these mice.

Implications for Cancer Treatment

The findings have immediate relevance for emerging “senolytic” therapies designed to eliminate senescent cells from aging bodies. While such treatments might offer benefits for age-related diseases, this research suggests they could have complex effects on cancer development and progression.

The study indicates that senescent cell elimination strategies need to be cell-type specific rather than broadly targeting all aging cells. Removing aged immune or connective tissue cells might provide benefits, while preserving functional blood vessels appears crucial for preventing metastasis.

Lead researcher Mikhail G. Kolonin emphasized the complexity revealed by the study: “This study shows that senescence and metabolic dysfunction resulting from telomerase inactivation in distinct cells in the tumor microenvironment have different effects on tumor growth and metastasizing of carcinomas.”

A New Framework for Understanding Cancer

The research provides a new lens for understanding why cancer becomes more common and often more aggressive with age. Rather than aging simply weakening the body’s defenses, it appears to create a complex ecosystem where different cellular changes can either help or hinder cancer progression.

This complexity may explain why many cancer studies conducted in young laboratory animals fail to capture the full picture of how tumors behave in older organisms. The vast majority of human cancer patients are over 65, yet most preclinical research uses young animals that may not reflect the aged tissue environment where most cancers actually develop.

The findings also suggest that cancer prevention and treatment strategies should account for the specific types of cellular aging occurring in different patients. Understanding which cells are becoming senescent, and in what patterns, could help predict cancer risk and guide more effective interventions.

As the population ages and senolytic therapies move toward clinical use, this research provides crucial guidance for developing treatments that harness the anti-cancer effects of some types of cellular aging while avoiding the pro-metastatic effects of others. The goal is no longer simply to fight aging, but to understand and work with its complex effects on cancer biology.